Boostrix Vaccine 6 month (201334)

The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 12-18 months of age to infants who received primary vaccination at 6-12 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 [DTPA (BOOSTRIX)-047].

Register Today!

Trial Information

Start DateJuly 2017
End DateTBD
Trial Duration9-10 months
Number of Visits3
Lead CRCJessica Richer

For additional information
on this trial contact: